<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154220">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01092273</url>
  </required_header>
  <id_info>
    <org_study_id>Prostaglandins-Cairo-1A</org_study_id>
    <nct_id>NCT01092273</nct_id>
  </id_info>
  <brief_title>Bimatoprost Versus Travoprost at Cairo University</brief_title>
  <official_title>Bimatoprost Versus Travoprost in an Egyptian Population: A Hospital-Based Prospective Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bimatoprost has been shown to provide effective IOP lowering in patients of all races.
      Conversely, travoprost has been shown to be more effective in black patients than in
      Caucasians in some studies. However, Noecker et al 2004 compared bimatoprost with travoprost
      in African-Americans with glaucoma or OHT, and found that bimatoprost was more likely than
      travoprost to achieve target pressure at 3 months.

      These racial differences in efficacy of these medications warrant further investigations.
      The investigators study aim to compare the IOP-lowering efficacies of bimatoprost and
      travoprost in an Egyptian population with primary open-angle glaucoma (OAG) or ocular
      hypertension (OHT).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of intraocular pressure lowering of bimatoprost versus travoprost.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of development of complications.</measure>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <condition>Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Bimatoprost versus Travoprost</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital Based Study at Cairo University and Al Nour Eye Hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Glaucoma and Ocular Hypertension

        Exclusion Criteria:

          -  Any ocular disease or medication that may raise the intraocular pressure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <zip>11431</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/19726422</url>
  </link>
  <verification_date>January 2008</verification_date>
  <lastchanged_date>March 23, 2010</lastchanged_date>
  <firstreceived_date>March 23, 2010</firstreceived_date>
  <keyword>Glaucoma and Ocular Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bimatoprost</mesh_term>
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
